Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
Eye on the Cure
Lance Baldo, MD, CEO at Beacon Therapeutics, is discussing his company’s gene therapy for XLRP.
September 26, 2025. Lance Baldo, MD, CEO at Beacon Therapeutics, talks to host Ben Shaberman about his company's fully enrolled Phase 3 VISTA clinical trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa (RPGR mutations) that has shown promising results in earlier trials. They also discuss Beacon's forthcoming clinical trial for its dry age-related macular degeneration gene therapy.
